Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H22N2OS |
Molecular Weight | 326.456 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCCN1C2=C(SC3=C1C=C(C=C3)C(C)=O)C=CC=C2
InChI
InChIKey=NOSIYYJFMPDDSA-UHFFFAOYSA-N
InChI=1S/C19H22N2OS/c1-14(22)15-9-10-19-17(13-15)21(12-6-11-20(2)3)16-7-4-5-8-18(16)23-19/h4-5,7-10,13H,6,11-12H2,1-3H3
Molecular Formula | C19H22N2OS |
Molecular Weight | 326.456 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Acepromazine a potent neuroleptic agent with a low order of toxicity, is of particular value in the tranquilization of dogs, cats and horses. Its rapid action and lack of hypnotic effect are added advantages. Acepromazine is a commonly used tranquilizer/sedative in dogs, cats, horses, and other animals. Veterinarians typically prescribe acepromazine to quiet agitated animals or use it as a part of an anesthetic protocol. It is important to note that when used alone, acepromazine is not an effective pain reliever and does little if anything to relieve a pet’s anxiety or fear. Acepromazine can also be used to treat motion sickness and nausea associated with car or plane rides. The mechanism by which acepromazine decreases a pet’s alertness is not fully understood. It is thought to block dopamine receptors in the brain or inhibit the activity of dopamine in other ways.
CNS Activity
Originator
Sources: Schmitt, J. et al.: Bull. Soc. Chim. Fr. (BSCFAS) 1957, 938, 1474.
Curator's Comment: reference retrieved from https://pharmaceutical-substances.thieme.com/ps/search-results?query=&sort=&searchValuesMode=session&page=1&docUri=KD-01-0015 | www.drugfuture.com/chemdata/acepromazine.html
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2096905 |
|||
Target ID: GO:0050877 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ACEPROMAZINE MALEATE Approved UseActions: Acepromazine maleate has a depressant effect on the central nervous system and therefore, causes sedation, muscular relaxation and a reduction in spontaneous activity. It acts rapidly, exerting a prompt and pronounced calming effect.
Indications: Dogs and Cats: Acepromazine Maleate Injection can be used as an aid in controlling intractable animals during examination, treatment, grooming, x-ray and minor surgical procedures; to alleviate itching as a result of skin irritation; as an antiemetic to control vomiting associated with motion sickness. Acepromazine Maleate Injection is particularly useful as a preanesthetic agent (1) to enhance and prolong the effects of barbiturates, thus reducing the requirements for general anesthesia; (2) as an adjunct to surgery under local anesthesia.
Horses: Acepromazine Maleate Injection can be used as an aid in controlling fractious animals during examination, treatment, loading and transportation. Particularly useful when used in conjunction with local anesthesia for firing, castration, neurectomy, removal of skin tumors, ocular surgery and applying casts. |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Application of pulsed Doppler ultrasound for the evaluation of small intestinal motility in dogs. | 2001 Apr |
|
Pulp histology after Er:YAG laser cavity preparation in subhuman primates--a pilot study. | 2002 Aug |
|
Combination therapy for footpad lesions in a captive Bengal tiger (Panthera tigris tigris). | 2002 Dec |
|
The brain matrix and multifocal brain damage following a single injection of ketamine in young adult rats: conspicuous changes in old age. | 2002 Dec |
|
Effects of treatment with oxytocin, xylazine butorphanol, guaifenesin, acepromazine, and detomidine on esophageal manometric pressure in conscious horses. | 2002 Dec |
|
In vitro effects of oxytocin, acepromazine, detomidine, xylazine, butorphanol, terbutaline, isoproterenol, and dantrolene on smooth and skeletal muscles of the equine esophagus. | 2002 Dec |
|
Cardiopulmonary effects of xylazine and acepromazine in pregnant cows in late gestation. | 2002 Dec |
|
Effects of medetomidine-midazolam, acepromazine-butorphanol, and midazolam-butorphanol on induction dose of thiopental and propofol and on cardiopulmonary changes in dogs. | 2002 Dec |
|
Central sympathetic blockade ameliorates brain death-induced cardiotoxicity and associated changes in myocardial gene expression. | 2002 Dec |
|
[Priapism in the stallion]. | 2002 Dec 15 |
|
The effects of xylazine, detomidine, acepromazine and butorphanol on equine solid phase gastric emptying rate. | 2002 Jul |
|
Evaluation of the perioperative stress response in dogs administered medetomidine or acepromazine as part of the preanesthetic medication. | 2002 Jul |
|
Cerebral blood volume measurements by rapid contrast infusion and T2*-weighted echo planar MRI. | 2002 Jun |
|
Structure of TAR RNA complexed with a Tat-TAR interaction nanomolar inhibitor that was identified by computational screening. | 2002 Jun |
|
Reduced resident time and pharmacodynamic effects of acepromazine after subclinical multiple dosage in exercised thoroughbreds. | 2002 Oct |
|
Effects of two preanesthetic regimens for ophthalmic surgery on intraocular pressure and cardiovascular measurements in dogs. | 2002 Spring |
|
Hematology and serum chemistry of the island spotted skunk on Santa Cruz Island. | 2003 Apr |
|
Effects of acepromazine on capture stress in roe deer (Capreolus capreolus). | 2003 Apr |
|
Postoperative hypoxemia and hypercarbia in healthy dogs undergoing routine ovariohysterectomy or castration and receiving butorphanol or hydromorphone for analgesia. | 2003 Feb 1 |
|
Effects of dopamine antagonists on alfentanil-induced locomotor activity in horses. | 2003 Jul |
|
Changes in the EEG during castration in horses and ponies anaesthetized with halothane. | 2003 Jul |
|
Hypotensive effect of push-pull gravitational stress occurs after autonomic blockade. | 2003 Jul |
|
Progressive changes in ophthalmic blood velocities in Beagles with primary open angle glaucoma. | 2003 Mar |
|
Changes in intraocular pressure and pupil size following intramuscular administration of hydromorphone hydrochloride and acepromazine in clinically normal dogs. | 2003 Mar |
|
Method for the noninvasive measurement of intraocular pressure in mice. | 2003 Mar |
|
Effects of acepromazine on renal function in anesthetized dogs. | 2003 May |
|
Temporal changes in ventricular function assessed echocardiographically in conscious and anesthetized mice. | 2003 Nov |
|
Effects of midazolam-butorphanol, acepromazine-butorphanol and medetomidine on an induction dose of propofol and their compatibility in dogs. | 2003 Oct |
|
A comparison of preoperative tramadol and morphine for the control of early postoperative pain in canine ovariohysterectomy. | 2003 Oct |
|
Analysis of phenothiazine and its derivatives using LC/electrochemistry/MS and LC/electrochemistry/fluorescence. | 2003 Sep 15 |
|
The effect of four anesthetic protocols on splenic size in dogs. | 2004 Apr |
|
Development of a rapid screening test for veterinary sedatives and the beta-blocker carazolol in porcine kidney by ELISA. | 2004 Feb |
|
The neuromatrix and the epileptic brain: behavioral and learning preservation in limbic epileptic rats treated with ketamine but not acepromazine. | 2004 Feb |
|
Ganglion cell contributions to the rat full-field electroretinogram. | 2004 Feb 15 |
|
Systemic lidocaine infusion as an analgesic for intraocular surgery in dogs: a pilot study. | 2004 Jan |
|
Evaluation of intraperitoneal and incisional lidocaine or bupivacaine for analgesia following ovariohysterectomy in the dog. | 2004 Jan |
|
Effects of acepromazine on the incidence of vomiting associated with opioid administration in dogs. | 2004 Jan |
|
Elevated nociceptive thresholds in rats with multifocal brain damage induced with single subcutaneous injections of lithium and pilocarpine. | 2004 Jun |
|
Middle-latency auditory-evoked potential in acepromazine-sedated dogs. | 2004 Mar-Apr |
|
Effects of various anesthetic agents on laryngeal motion during laryngoscopy in normal dogs. | 2004 Mar-Apr |
|
Normal spatial and contextual learning for ketamine-treated rats in the pilocarpine epilepsy model. | 2004 May |
|
Effects of doxapram HCl on laryngeal function of normal dogs and dogs with naturally occurring laryngeal paralysis. | 2004 Oct |
|
Therapeutic effects of Holmium-166 chitosan complex in rat brain tumor model. | 2005 Feb 28 |
|
Overdose during chemical restraint in a black rhinoceros (Diceros bicornis). | 2005 Jan |
|
Laparoscopic nonanatomic hepatic resection employing the LigaSure device. | 2005 Jan-Mar |
|
Effects of acepromazine on pulmonary gas exchange and circulation during sedation and dissociative anaesthesia in horses. | 2005 Mar |
|
Muscle metabolic changes associated with long-term inhalation anaesthesia in the horse analysed by muscle biopsy and microdialysis techniques. | 2005 Mar |
|
Results of 24-hour ambulatory electrocardiography in dogs undergoing ovariohysterectomy following premedication with medetomidine or acepromazine. | 2005 Mar 1 |
|
Analgesic efficacy of preoperative administration of meloxicam or butorphanol in onychectomized cats. | 2005 Mar 15 |
|
Gamma scintigraphic evaluation of a miniaturized AERx pulmonary delivery system for aerosol delivery to anesthetized animals using a positive pressure ventilation system. | 2005 Spring |
Patents
Sample Use Guides
Acepromazine Maleate Injection may be given intravenously, intramuscularly or subcutaneously. The following schedule may be used as a guide to IV, IM or SC injections:
Dogs: 0.25-0.5 mg/lb of body weight.
Cats: 0.5-1 mg/lb of body weight.
Horses: 2-4 mg/100 lb of body weight.
0.25 - 3 mg per kg body weight by oral administration.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28404253
The crude extract of Chlamydia pneumoniae induced the differentiation of monocytes into macrophages in 45 ± 5% of the cells. Acepromazine significantly reduced the mean percentage of differentiated cells: with 10−5 M ACP, 18 ± % (p < 0.005) of the cells differentiated into macrophages and with 10−4 M the mean percentage of differentiated cells was equivalent to the control values: 5 ± 1% (p < 0.001). Viability of the differentiated and nondifferentiated THP-1 was = 98%.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:15:27 GMT 2023
by
admin
on
Fri Dec 15 16:15:27 GMT 2023
|
Record UNII |
54EJ303F0R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN05AA04
Created by
admin on Fri Dec 15 16:15:28 GMT 2023 , Edited by admin on Fri Dec 15 16:15:28 GMT 2023
|
||
|
WHO-ATC |
N05AA04
Created by
admin on Fri Dec 15 16:15:28 GMT 2023 , Edited by admin on Fri Dec 15 16:15:28 GMT 2023
|
||
|
NCI_THESAURUS |
C66883
Created by
admin on Fri Dec 15 16:15:28 GMT 2023 , Edited by admin on Fri Dec 15 16:15:28 GMT 2023
|
||
|
CFR |
21 CFR 522.23
Created by
admin on Fri Dec 15 16:15:28 GMT 2023 , Edited by admin on Fri Dec 15 16:15:28 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL39560
Created by
admin on Fri Dec 15 16:15:28 GMT 2023 , Edited by admin on Fri Dec 15 16:15:28 GMT 2023
|
PRIMARY | |||
|
54EJ303F0R
Created by
admin on Fri Dec 15 16:15:28 GMT 2023 , Edited by admin on Fri Dec 15 16:15:28 GMT 2023
|
PRIMARY | |||
|
155
Created by
admin on Fri Dec 15 16:15:28 GMT 2023 , Edited by admin on Fri Dec 15 16:15:28 GMT 2023
|
PRIMARY | RxNorm | ||
|
C77568
Created by
admin on Fri Dec 15 16:15:28 GMT 2023 , Edited by admin on Fri Dec 15 16:15:28 GMT 2023
|
PRIMARY | |||
|
73
Created by
admin on Fri Dec 15 16:15:28 GMT 2023 , Edited by admin on Fri Dec 15 16:15:28 GMT 2023
|
PRIMARY | |||
|
54EJ303F0R
Created by
admin on Fri Dec 15 16:15:28 GMT 2023 , Edited by admin on Fri Dec 15 16:15:28 GMT 2023
|
PRIMARY | |||
|
61-00-7
Created by
admin on Fri Dec 15 16:15:28 GMT 2023 , Edited by admin on Fri Dec 15 16:15:28 GMT 2023
|
PRIMARY | |||
|
44932
Created by
admin on Fri Dec 15 16:15:28 GMT 2023 , Edited by admin on Fri Dec 15 16:15:28 GMT 2023
|
PRIMARY | |||
|
667
Created by
admin on Fri Dec 15 16:15:28 GMT 2023 , Edited by admin on Fri Dec 15 16:15:28 GMT 2023
|
PRIMARY | |||
|
D000075
Created by
admin on Fri Dec 15 16:15:28 GMT 2023 , Edited by admin on Fri Dec 15 16:15:28 GMT 2023
|
PRIMARY | |||
|
m1303
Created by
admin on Fri Dec 15 16:15:28 GMT 2023 , Edited by admin on Fri Dec 15 16:15:28 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID1022552
Created by
admin on Fri Dec 15 16:15:28 GMT 2023 , Edited by admin on Fri Dec 15 16:15:28 GMT 2023
|
PRIMARY | |||
|
6077
Created by
admin on Fri Dec 15 16:15:28 GMT 2023 , Edited by admin on Fri Dec 15 16:15:28 GMT 2023
|
PRIMARY | |||
|
100000087916
Created by
admin on Fri Dec 15 16:15:28 GMT 2023 , Edited by admin on Fri Dec 15 16:15:28 GMT 2023
|
PRIMARY | |||
|
DB01614
Created by
admin on Fri Dec 15 16:15:28 GMT 2023 , Edited by admin on Fri Dec 15 16:15:28 GMT 2023
|
PRIMARY | |||
|
200-496-0
Created by
admin on Fri Dec 15 16:15:28 GMT 2023 , Edited by admin on Fri Dec 15 16:15:28 GMT 2023
|
PRIMARY | |||
|
SUB05213MIG
Created by
admin on Fri Dec 15 16:15:28 GMT 2023 , Edited by admin on Fri Dec 15 16:15:28 GMT 2023
|
PRIMARY | |||
|
ACEPROMAZINE
Created by
admin on Fri Dec 15 16:15:28 GMT 2023 , Edited by admin on Fri Dec 15 16:15:28 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
|
||
|
TRANSPORTER -> SUBSTRATE |
Increased sedation seen in dogs with the ABCB1-1Δ mutation.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|